GSK's Votrient Will Need To Show Efficacy Outweighs Black Box
The sixth drug approved to treat renal cell carcinoma, Votrient wins approval just two weeks after a unanimous endorsement from FDA's Oncologic Drugs Advisory Committee.
The sixth drug approved to treat renal cell carcinoma, Votrient wins approval just two weeks after a unanimous endorsement from FDA's Oncologic Drugs Advisory Committee.